Who is sponsoring NCT03110588?

NCT03110588 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT03110588?

Interventions in NCT03110588: PACE with Cabazitaxel (15 mg/m2), PACE with Cabazitaxel (20 mg/m2).

What condition does NCT03110588 study?

NCT03110588 studies Metastatic Prostate Cancer.

Is NCT03110588 still recruiting?

NCT03110588 is currently withdrawn. Last updated 19 October 2020.

Last reviewed 2020-10-19 · How we verify

NCT03110588

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Trial of PACE for Metastatic Prostate Cancer

Withdrawn Phase 1 Last updated 19 October 2020

What this trial tests

Phase 1 trial testing PACE with Cabazitaxel (15 mg/m2) in Metastatic Prostate Cancer. Withdrawn.

Timeline

9 May 2018

Primary endpoint
18 December 2019

18 December 2019

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Start date	9 May 2018
Primary completion	18 December 2019
Estimated completion	18 December 2019
Sites	1 location across United States

Drugs / interventions tested

PACE with Cabazitaxel (15 mg/m2) — full drug profile →
PACE with Cabazitaxel (20 mg/m2) — full drug profile →

Conditions studied

Metastatic Prostate Cancer — all drugs for Metastatic Prostate Cancer →

Sponsor

University of Alabama at Birmingham

Who can join

18 and older, male only, with Metastatic Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is being conducted to determine the feasibility and recommended dose of the combination of four drugs (prednisone, abiraterone, cabazitaxel and enzalutamide (PACE) as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions.
Tucci M, Zichi C, Buttigliero C, Vignani F, et al · · 2018 · cited 62× · PMID 30425524 · DOI 10.2147/ott.s153764
Targeting treatment options for castration-resistant prostate cancer.
Miller DR, Ingersoll MA, Teply BA, Lin MF. · · 2021 · cited 20× · PMID 33816699
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations.
Patel SA, Hoffman-Censits J. · · 2017 · cited 4× · PMID 28860817 · DOI 10.2147/ott.s103532

Verify or expand the search:

Other recruiting trials for Metastatic Prostate Cancer

Currently open trials in the same condition.

NCT07145177 — 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer · Phase 1 · recruiting
NCT07290270 — Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN) · recruiting
NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
NCT07209176 — Physician- and Patient-based Barriers to NGS Testing · NA · recruiting
NCT07181161 — Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer · Phase 1, PHASE2 · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03110588 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 19 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03110588.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing